1. Search Result
Search Result
Results for "

ATM gene

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-157941

    ATM/ATR Checkpoint Kinase (Chk) DNA/RNA Synthesis Cancer
    ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC50 of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .
    ART0380
  • HY-103241
    Ro 90-7501
    3 Publications Verification

    Amyloid-β ATM/ATR Phosphatase Apoptosis Neurological Disease Cancer
    Ro 90-7501 is an amyloid β42 (Aβ42) fibril assembly inhibitor that reduces 42-induced cytotoxicity (EC50 of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .
    Ro 90-7501
  • HY-163944

    DNA/RNA Synthesis Molecular Glues CDK Apoptosis RAD51 ATM/ATR PARP Cancer
    LL-K12-18 is a CDK12 kinase inhibitor and a dual-site molecular glue. LL-K12-18 inhibits human CDK12 with an IC50 value of 283.9 nM, and selectively degrades cyclin K via the ubiquitin-proteasome system by stabilizing the CDK12-DDB1 complex. LL-K12-18 downregulates DNA damage response genes, reduces the phosphorylation level of CTD Ser2 in RNA polymerase II, and modulates biomarkers such as ATM, RAD51, γ-H2AX and cleaved PARP, thereby effectively inducing apoptosis and inhibiting proliferation of breast cancer cells. LL-K12-18 exhibits high target selectivity and serves as a research tool for studies on triple-negative breast cancer .
    LL-K12-18
  • HY-123359

    DNA/RNA Synthesis Dystrophin Others
    RTC14 is a read-through compound (RTC) that can induce ribosomes to bypass nonsense mutations in mRNA and allow the production of full-length functional proteins. RTC14 has the potential to be used in the research of various genetic disorders, such as nonsense mutations in the ataxia-telangiectasia mutated (ATM) gene and the dystrophin gene .
    RTC14
  • HY-126210

    Biochemical Assay Reagents Others
    GJ072 is a read-through compound (RTCs). GJ072 can induce “readthrough” .
    GJ072
  • HY-RS01161

    Small Interfering RNA (siRNA) Others

    Atm Mouse Pre-designed siRNA Set A contains three designed siRNAs for Atm gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Atm Mouse Pre-designed siRNA Set A
    Atm Mouse Pre-designed siRNA Set A
  • HY-RS01162

    Small Interfering RNA (siRNA) Others

    Atm Rat Pre-designed siRNA Set A contains three designed siRNAs for Atm gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Atm Rat Pre-designed siRNA Set A
    Atm Rat Pre-designed siRNA Set A
  • HY-RS01160

    Small Interfering RNA (siRNA) Others

    ATM Human Pre-designed siRNA Set A contains three designed siRNAs for ATM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ATM Human Pre-designed siRNA Set A
    ATM Human Pre-designed siRNA Set A
  • HY-173147

    CDK Cancer
    CDK2-IN-42 (Compound H63) is a CDK12 inhibitor with an IC50 value of 10 nM. CDK2-IN-42 has anti-ESCC (Esophageal Squamous Cell Carcinoma) cell activity. It can block transcriptional elongation, downregulate the core genes in the G1 phase to induce cell cycle arrest, and alter the CDK12-ATM/ATR-CHEK1/CHEK2 signaling axis, resulting in DNA damage. CDK2-IN-42 can effectively inhibit tumor growth in a xenograft mouse model of human ESCC KYSE150. CDK2-IN-42 holds great promise for research in the field of cancer .
    CDK2-IN-42
  • HY-181035

    PROTACs CDK Cancer
    DN1679 is a potent, selective and orally active CRBN-dependent CDK12/13 PROTAC dual degrader. DN1679 shows DC50 of 8.8/9.8 nM (MDA-MB-231), 5.1/6.4 nM (MDA-MB-157) and 17.2/15.8 nM (MDA-MB-468) for CDK12/13. DN1679 can downregulate DNA damage response gene mRNA levels, such as ATM, ATR, BRCA1 and RAD51. DN1679 demonstrates a potent synergistic anti-tumor effect companied with Olaparib (HY-10162). DN1679 can be used for research of triple-negative breast cance .
    DN1679
  • HY-103241R

    Reference Standards Amyloid-β ATM/ATR Phosphatase Apoptosis Neurological Disease Cancer
    Ro 90-7501 (Standard) is the analytical standard of Ro 90-7501 (HY-103241). This product is intended for research and analytical applications. Ro 90-7501 is an amyloid β42 (Aβ42) fibril assembly inhibitor that reduces Aβ42-induced cytotoxicity (EC50 of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .
    Ro 90-7501 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: